Introduction
Even though enterococci, which are normal human commensals, are less virulent than certain other Gram-positive bacteria, they have been recognized as important causes of nosocomial and community-acquired diseases. Enterococcus faecalis causes 80-90% of human enterococcal infections, while Enterococcus faecium and Enterococcus durans account for a majority of the remainder. 1 Such infections may be difficult to treat because of intrinsic or acquired resistance of enterococci to many antimicrobial agents, 2 prompting the search for new drugs. Ketolides are a new class of semi-synthetic 14-membered-ring macrolides, active against respiratory tract pathogens and also enterococci. 3, 4 Introduction of a fluorine moiety in position 2 of the macrolactone skeleton improves the overall antibacterial spectrum, as reported previously for novel 2-fluoro-ketolides, 5 such as HMR 3562. Here, we focused on the in vitro and in vivo antibacterial activity of HMR 3562 against enterococci, including vancomycin-resistant strains.
Materials and methods

Antibiotics
HMR 3562, erythromycin A, clarithromycin and azithromycin were prepared by Aventis (Romainville, France). Pristinamycin was provided by Aventis (Vitry, France). Teicoplanin and vancomycin were purchased from Sigma (St Louis, MO, USA).
Bacterial strains
Ninety-five strains were tested: 51 E. faecalis, 40 E. faecium, two Enterococcus gallinarum, one E. durans and one Enterococcus casseliflavus. Thirty-six isolates were vancomycin resistant. All the strains tested were clinical isolates from various European and US hospitals, except the reference strain E. faecalis ATCC 29212 used for quality control.
MIC determination
MICs were measured by a two-fold agar dilution method in Mueller-Hinton (MH) agar medium (pH 7.4; Diagnostic Pasteur, France). 6 A standard inoculum of 10 4 cfu/spot was used throughout the study. All plates were incubated at 37ЊC for 24 h. The MIC was defined as the lowest concentration at which no visible growth could be detected on agar plates. According to NCCLS breakpoints, MICs for susceptible strains were р0.5, р4 and р8 mg/L for erythromycin, vancomycin and teicoplanin, respectively.
Systemic infection model
The present studies were approved by the Internal Animal Ethics Committee. Male C3H and C57Bl/6 Charles River mice were used to study the antibacterial activity of compounds in a peritonitis model against vancomycin-susceptible and -resistant strains, respectively. Each dosing group was composed of 10 animals weighing 20-22 g. Mice were infected intraperitoneally with 0. 
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culture suspended in physiological buffer containing 5% pig mucin (Sigma) to a final cell density corresponding to 10-100 times the minimal lethal dose, i.e. approximately 10 9 cfu. Bovine haemoglobin (2%) (Sigma) was added when testing vancomycin-resistant strains. Under these conditions, untreated animals died by 48-72 h. Suspensions of compounds (0.5 mL) were administered in carboxymethyl cellulose (Sigma) by the oral route, except for vancomycin, immediately and 4 h post-infection. Vancomycin was administered subcutaneously in saline buffer. Mice were observed for 8-10 days following the inoculation, and the 50% protective dose (PD 50 ) expressed as the unit dose that protected 50% of the animals from death was calculated by the probit method of Litchfield & Wilcoxon. 
Results
In vitro susceptibility results
PD 50 determinations
Discussion
The emergence of virulent isolates of enterococci with high levels of intrinsic penicillin resistance has limited the use of -lactams as first line therapy. Although new quinolones may be more active, they still remain contraindicated in pregnant women or young children. In contrast, macrolides are usually considered as safe antibacterial agents. Structural changes in ketolides render them drastically different from macrolides, particularly in their activity against multiresistant Gram-positive cocci, with telithromycin (HMR 3647) being active against enterococci. 4 In the search for new compounds, the 2-fluoro analogue of telithromycin, HMR 3562, has been synthesized.
As shown previously, 8, 9 HMR 3562 displayed potent activity against E. faecalis and E. faecium, irrespective of their erythromycin A susceptibility status. The MIC 90 of HMR 3562 for erythromycin A-resistant enterococci was 0.6 mg/L, while all of the macrolides tested remained inactive. As vancomycin resistance is commonly associated with macrolide resistance in enterococci, it is worth noting that HMR 3562 remained active against vancomycinresistant strains. However, as with telithromycin and macrolides, 4 HMR 3562 demonstrated bacteriostatic activity against both erythromycin A-susceptible and erythromicin A-resistant strains (data not shown).
There is little published information about therapy of enterococci in murine models, particularly with ketolides. 3, 10 In experimental peritonitis, we confirmed the in vitro activity of HMR 3562, with consistent efficacy against all of the five strains tested, irrespective of their macrolide resistance phenotype. The PD 50 range was 3.4-21.8 mg/kg, while MICs ranged from 0.01 to 0.15 mg/L. On the other hand, despite its favourable MICs, pristinamycin did not show any therapeutic efficacy at the doses tested, probably due to disadvantageous kinetics.
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In conclusion, HMR 3562 shows promise as an antimicrobial agent for use against multi-resistant enterococci. 
